Harmony Biosciences Holdings Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
HRMY$33.78+2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| | | | | | | |
|---|---|---|---|---|---|---|
| · December 31, · December 31, | ||||||
| · 2024 · 2023 | ||||||
| ASSETS · · | ||||||
| CURRENT ASSETS: · · | ||||||
| Cash and cash equivalents | | $453,001 | | $311,660 | ||
| Investments, short-term | | | 14,185 | | | 41,800 |
| Trade receivables, net | | 83,033 | | 74,140 | ||
| Inventory, net | | 7,198 | | 5,363 | ||
| Prepaid expenses | | 13,714 | | 12,570 | ||
| Other current assets | | 8,121 | | 5,537 | ||
| Total current assets | | 579,252 | | 451,070 | ||
| NONCURRENT ASSETS: | | | ||||
| Property and equipment, net | | 1,257 | | 371 | ||
| Restricted cash | | 270 | | 270 | ||
| Investments, long-term | | | 108,874 | | | 72,169 |
| Intangible assets, net | | 113,263 | | 137,108 | ||
| Deferred tax asset | | | 190,398 | | | 144,162 |
| Other noncurrent assets | | 5,886 | | 6,298 | ||
| Total noncurrent assets | | 419,948 | | 360,378 | ||
| TOTAL ASSETS | | $999,200 | | $811,448 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | ||||
| CURRENT LIABILITIES: | | | ||||
| Trade payables | | $13,744 | | $17,730 | ||
| Accrued compensation | | 18,776 | | 23,747 | ||
| Accrued expenses | | 120,640 | | 99,494 | ||
| Current portion of long-term debt | | | 16,250 | | | 15,000 |
| Other current liabilities | | 5,672 | | 7,810 | ||
| Total current liabilities | | 175,082 | | 163,781 | ||
| NONCURRENT LIABILITIES: | | | ||||
| Long-term debt, net | | 163,016 | | 178,566 | ||
| Other noncurrent liabilities | | 1,947 | | 2,109 | ||
| Total noncurrent liabilities | | 164,963 | | 180,675 | ||
| TOTAL LIABILITIES | | 340,045 | | 344,456 | ||
| COMMITMENTS AND CONTINGENCIES (Note 13) | | | ||||
| STOCKHOLDERS’ EQUITY: | | | ||||
| Common stock—$0.00001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; 57,144,887 and 56,769,081 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | | 1 | | 1 | ||
| Additional paid in capital | | 656,872 | | 610,266 | ||
| Accumulated other comprehensive (loss) income | | | 66 | | | 2 |
| Retained earnings (accumulated deficit) | | 2,216 | | (143,277) | ||
| TOTAL STOCKHOLDERS’ EQUITY | | 659,155 | | 466,992 | ||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | | $999,200 | | $811,448 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.